Loxo@Lilly’s Post

����������The new TSO 500 ctDNA version 2 is available now! It delivers faster turnaround times, greater analytical sensitivity & streamline workflow to enable #CGP of solid tumors, all from a blood sample!#NGS #liquidbiopsy @ #illumina Watch this video��� #cancer #oncology #oncologyresearch https://lnkd.in/d2kQ7mbz

CLINICAL SIGNIFICANCE OF NRF2 AND KEAP1 EXPRESSIONS IN NON SMALL CELL LUNG CARCINOMA, Poster Presentation, 1st International Basic Oncology Congress, (02 June 2022, 04 June 2022) 

In an Applied Clinical Trials Magazine article, our VP of Oncology, Ravi Karra, discusses how we can overcome challenges in early phase drug development for solid tumors. Read now: https://hubs.la/Q02KY1V10 #Oncology #SolidTumors #ClinicalTrials #DrugDevelopment

Encouraging activity in CCNE activated ovarian and endometrial cancers

New research from GRAIL highlights that a methylation-based cfDNA assay can predict poor outcomes and higher PD-L1 expression in early stage (Stage I & Stage II) LUAD patients, suggesting benefits from immune checkpoint inhibitors. So, why it matters? ctDNA/MRD detection reflects dynamics of tumor burden so that physicians could identify remission or progression of disease in time and can handle the duration of neoadjuvant treatment more precisely in case of early stages of LUAD. And the study highlights the importance of early cancer detection utilizing ctDNA testing for identifying high-risk patients and tailoring personalized treatments in early-stage NSCLC. Also highlights the need of integration of ctDNA testing into routine diagnostic workflows in early-stage NSCLC without the need of tumor tissue profiling. #LungCancer #ctDNA #PersonalizedMedicine #EarlyCancerDetection

Post-SMR Congress, we asked Dr. Vernon Sondak what the Castle Biosciences Decision DX melanoma test could mean for patient testing. Here’s what he had to say. Don't miss out on the latest developments in oncology! Let us show you how we can get the insights you need from the experts you want to hear from. #OnvivExpertNetwork #SMR2024 #CongressInsights #Melanoma

Watch as a panel of experts in gynecologic oncology as they review recent data from the 2023 ASCO Annual Meeting and discusses the evolving treatment landscape. #ASCO23 #gyncsm https://lnkd.in/e8bEbHgM

Are combination therapies in oncology the future of CAR T-cell therapy for solid tumors? Research has shown that combinatorial approaches with CAR T-cell therapy can overcome heterogeneity in solid tumors. Read our scientific spotlight to learn more about the benefits of combination therapies and how we can support your next discovery oncology program. Learn more:

Are combination therapies in oncology the future of CAR T-cell therapy for solid tumors? Research has shown that combinatorial approaches with CAR T-cell therapy can overcome heterogeneity in solid tumors. Read our scientific spotlight to learn more about the benefits of combination therapies and how we can support your next discovery oncology program. Learn more:

Our editorial on the potential role of ctDNA in resectable NSCLC undergoing neo-adj chemo - Alessandro Russo #AnnalsOfOncology #Cancer #CtDNA #NSCLC #OncoDaily #Oncology